Browse Drug Recalls
10 FDA drug safety recalls.
FDA Drug Recall Enforcement Database
Browse 10 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.
Drug Safety Recalls
Browse 10 FDA drug recalls.
| Date | Product | Reason | Class | Firm |
|---|---|---|---|---|
| Dec 22, 2016 | Furosemide Tablets USP, 20 mg, 1000 count bottles, Rx only, Roxane Laboratori... | Failed Tablet/Capsule Specifications: An unusually thick tablet was reported through a complaint. | Class II | Roxane Laboratories, Inc. |
| Dec 14, 2016 | Azelastine Hydrochloride Nasal Solution (Nasal Spray), 0.1% (137 mcg per spra... | Defective Delivery System: out of specification result for droplet size distribution at the d90 m... | Class III | Roxane Laboratories, Inc. |
| Oct 6, 2016 | DIPYRIDAMOLE Tablets USP, 75 mg, 100-count bottle, Rx only, Dist. by: Roxane ... | Presence of foreign tablets/capsules: 50 mg Persantine tablets were found in a 75 mg Persantine 1... | Class II | Boehringer Ingelheim Pharmaceuticals, Inc. |
| Sep 25, 2015 | FUROSEMIDE Tablets USP, 40 mg, 1000-count bottle, Rx only, Boehringer Ingelhe... | CGMP Deviations: The active pharmaceutical ingredient (API) intended for use in furosemide oral s... | Class III | Boehringer Ingelheim Roxane Inc |
| Sep 25, 2015 | FUROSEMIDE Tablets USP, 20 mg, 1000-count bottle, Rx only, Boehringer Ingelhe... | CGMP Deviations: The active pharmaceutical ingredient (API) intended for use in furosemide oral s... | Class III | Boehringer Ingelheim Roxane Inc |
| Apr 2, 2015 | Acarbose Tablets 50 mg a)10 x 10 Unit Dose Tablets per Blister Pack, b)100 co... | Subpotent Drug: The firm received an out of specification result for Assay (potency was below spe... | Class II | Boehringer Ingelheim Roxane Inc |
| Jul 28, 2014 | OXYCODONE HYDROCHLORIDE C II Oral Solution USP, 5 mg/5 mL, 15 mL Vial, Rx onl... | Failed Stability Specifications: Out of specification result for preservative sodium benzoate. | Class III | Boehringer Ingelheim Roxane Inc |
| May 1, 2014 | Calcitriol Oral Solution 1 mcg/mL, 15mL bottle, Rx only, Roxane Laboratories,... | Failed Impurity/Degradation Specification; out of specification for trans-calcitriol degradant at... | Class II | Boehringer Ingelheim Roxane Inc |
| Apr 3, 2013 | Oxcarbazepine Oral Suspension, 300 mg/5 mL, 250 mL bottle, Rx only, Boehringe... | Resuspension Problems: Recalled lot did not meet resuspendability requirements. | Class II | Boehringer Ingelheim Roxane Inc |
| Mar 18, 2013 | Oxcarbazepine Tablets, 150 mg, packaged in a) 10 x 10 count Unit-Dose Tablets... | SubPotent Drug: The firm discovered out of specification results for assay and the extended inves... | Class III | Boehringer Ingelheim Roxane Inc |
Frequently Asked Questions
When a drug safety issue is identified, through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks, the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.
The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.
Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.